Optimization of Stability Indicating LC Method for the Sensitive In vitro Determination from Solid Lipid Nanoparticles and Ex vivo Analysis from Rat Skin of Etofenamate
Etofenamate (2-(2-hydroxyethoxy) ethyl 2-[[3-(trifluoromethyl)phenyl]amino]benzoate) (ETO) is a yellowish viscous liquid which is a nonsteroidal anti-inflammatory drug (NSAID) that has been applied topically for joint and muscular pain and soft tissue disorders. Solid lipid nanoparticles (SLNs) are colloidal drug delivery systems prepared by non-irritant and nontoxic lipids that attract great interest because of their unique features. Semisolid SLNs are novel approach for dermal application of SLNs. The aim of this study was to show the development, validation, and application of a simple, selective and reliable RP-LC method that was extensively validated for its specificity and stability-indicating properties from its forced hydrolytic, oxidative, photolytic and thermal degradation products. In addition, the proposed method presented to application of ETO from rat skin extract in according to the United States Pharmacopeia and International Council on Harmonization Guidelines. For this reason, XSelect HSS T3 XP (150 x 4.6 mm ID x 2.5µm) (Waters Corp. Milford, MA, USA) analytical column was chosen for the best resolution. Mobile phase consisted of 0.1 % H3PO4 in bidistilled water (pH adjusted to 7.0 with 5M NaOH) and acetonitrile in the ratio of (40:60, v/v) with the flow rate of 1 mL.min-1. The volume of the sample solutions was injected at 10μL and the detector was set up at 285 nm. The analysis was carried out at a temperature of 45°C. </p><p> The developed stability indicating method presented low limit of detection, low limit of quantitation and good resolution between any of interferences from both commercial formulation and developed SLN formulation from rat skin, with symmetric, pure and perfect peak homogeneity. High percentage of recovery results shows that the proposed method is free from the interferences of the commonly used excipients and additives in the formulations of the commercial product or semisolid SLN formulations and also biological derivatives..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Current pharmaceutical analysis - 13(2017), 1, Seite 63-71 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gumustas, Mehmet [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1986715965 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC1986715965 | ||
| 003 | DE-627 | ||
| 005 | 20230518181140.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 170131s2017 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a fidpha_zeitschriften_20170130.pp |
| 035 | |a (DE-627)OLC1986715965 | ||
| 035 | |a (DE-599)GBVOLC1986715965 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Gumustas, Mehmet |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Optimization of Stability Indicating LC Method for the Sensitive In vitro Determination from Solid Lipid Nanoparticles and Ex vivo Analysis from Rat Skin of Etofenamate |
| 264 | 1 | |c 2017 | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Etofenamate (2-(2-hydroxyethoxy) ethyl 2-[[3-(trifluoromethyl)phenyl]amino]benzoate) (ETO) is a yellowish viscous liquid which is a nonsteroidal anti-inflammatory drug (NSAID) that has been applied topically for joint and muscular pain and soft tissue disorders. Solid lipid nanoparticles (SLNs) are colloidal drug delivery systems prepared by non-irritant and nontoxic lipids that attract great interest because of their unique features. Semisolid SLNs are novel approach for dermal application of SLNs. The aim of this study was to show the development, validation, and application of a simple, selective and reliable RP-LC method that was extensively validated for its specificity and stability-indicating properties from its forced hydrolytic, oxidative, photolytic and thermal degradation products. In addition, the proposed method presented to application of ETO from rat skin extract in according to the United States Pharmacopeia and International Council on Harmonization Guidelines. For this reason, XSelect HSS T3 XP (150 x 4.6 mm ID x 2.5µm) (Waters Corp. Milford, MA, USA) analytical column was chosen for the best resolution. Mobile phase consisted of 0.1 % H3PO4 in bidistilled water (pH adjusted to 7.0 with 5M NaOH) and acetonitrile in the ratio of (40:60, v/v) with the flow rate of 1 mL.min-1. The volume of the sample solutions was injected at 10μL and the detector was set up at 285 nm. The analysis was carried out at a temperature of 45°C. </p><p> The developed stability indicating method presented low limit of detection, low limit of quantitation and good resolution between any of interferences from both commercial formulation and developed SLN formulation from rat skin, with symmetric, pure and perfect peak homogeneity. High percentage of recovery results shows that the proposed method is free from the interferences of the commonly used excipients and additives in the formulations of the commercial product or semisolid SLN formulations and also biological derivatives. | ||
| 700 | 1 | |a Sengel-Turk, C. Tuba |e verfasserin |4 aut | |
| 700 | 1 | |a Badilli, Ulya |e verfasserin |4 aut | |
| 700 | 1 | |a Amasya, Gulin |e verfasserin |4 aut | |
| 700 | 1 | |a Ozkan, Sibel Aysil |e verfasserin |4 aut | |
| 700 | 1 | |a Tarimci, Nilufer |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical analysis |d Sharjah : Bentham Sc. Publ., 2005 |g 13(2017), 1, Seite 63-71 |w (DE-627)486563324 |w (DE-600)2188299-X |w (DE-576)435514342 |x 1573-4129 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2017 |g number:1 |g pages:63-71 |
| 856 | 4 | 0 | |u http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1573-4129&volume=13&issue=1&spage=63 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 13 |j 2017 |e 1 |h 63-71 | ||